Episode
ADCs in Triple Negative Breast Cancer - Patient Management Strategies
- Published
- Sep 22, 2023
- Duration seconds
- 1538
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/nursing-excellence-in-cancer-care-cancer-nurses-society-of-australia-podcast-6586861/episodes/adcs-in-triple-negative-breast-cancer-patient-management-strategies/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/nursing-excellence-in-cancer-care-cancer-nurses-society-of-australia-podcast-6586861/adcs-in-triple-negative-breast-cancer-patient-management-strategies.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In the second episode of the Cancer Nurses Society of Australia podcast series, we discuss Antibody- Drug Conjugates (ADCs) . ADCs are a new type of cancer treatment that combines the targeting ability of antibodies with the potency of chemotherapy drugs. Justin Hargreaves Medical Oncology Nurse Practitioner, Bendigo Health Cancer Centre and Chair of the CNSA Specialist Practice Network is joined by Gillian Kruss, Metastatic Breast Cancer Nurse Practitioner at Monash Health and Marissa Stevens, Oncology Nurse Practitioner at St Vincent’s Hospital in Melbourne, to discuss the latest advances in ADC therapy and specifically the nursing management of metastatic triple negative breast cancer patients who are receiving Trodelvy (Sacituzumab govitecan).